Literature DB >> 12663232

Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.

Herbert Tilg1, Rajiv Jalan, Arthur Kaser, Nathan A Davies, Felix A Offner, Stephen J Hodges, Othmar Ludwiczek, Deborah Shawcross, Heinz Zoller, Akeel Alisa, Rajeshwar P Mookerjee, Ivo Graziadei, Christian Datz, Michael Trauner, Detlef Schuppan, Peter Obrist, Wolfgang Vogel, Roger Williams.   

Abstract

BACKGROUND/AIMS: Severe alcoholic hepatitis (AH) is associated with high mortality. Tumor necrosis factor-alpha (TNFalpha) has been demonstrated to play an important role in its pathophysiology.
METHODS: Twelve patients with biopsy-confirmed AH and a Maddrey discriminant factor >32 were treated with a single infusion of the anti-TNF monoclonal antibody Infliximab at a dose of 5mg/kg body weight. Serial measurements were made for various cytokines using specific enzyme-linked immunoassays (ELISA). In four patients, liver biopsy samples were available pretreatment and on day+28 of therapy.
RESULTS: Ten of the 12 patients are alive at a median of 15 (12-20) months. Two patients died within 30 days from septicemia. Serum bilirubin levels, Maddrey score, neutrophil count and C-reactive protein fell significantly within the first month. There was an early, though not significant, decrease in plasma levels of proinflammatory cytokines (interleukins (IL)-1beta, IL-6, IL-8, interferon-gamma), whereas plasma levels of TNFalpha remained near the sensitivity limit of the assay throughout the treatment course. While TNFalpha mRNA expression in the liver did not change, expression of IL-8, a cytokine regulated mainly by TNFalpha, was almost absent on day+28.
CONCLUSIONS: Our data suggest that randomized controlled trials of anti-TNF antibody in severe AH are warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663232     DOI: 10.1016/s0168-8278(02)00442-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  58 in total

Review 1.  Cirrhosis: new research provides a basis for rational and targeted treatments.

Authors:  John P Iredale
Journal:  BMJ       Date:  2003-07-19

Review 2.  Immunological response in alcoholic liver disease.

Authors:  Michael J Duryee; Lynell W Klassen; Geoffrey M Thiele
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

Review 3.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 4.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

5.  The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes.

Authors:  Pranoti Mandrekar; Shashi Bala; Donna Catalano; Karen Kodys; Gyongyi Szabo
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

Review 6.  Review.

Authors:  Maureen M Jonas; Christine Lee
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-02

Review 7.  Extracorporeal liver support in severe alcoholic hepatitis.

Authors:  Albert Parés; Antoni Mas
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

Review 8.  Immune dysfunction in acute alcoholic hepatitis.

Authors:  Ashwin D Dhanda; Peter L Collins
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.

Authors:  R P Mookerjee; S Sen; N A Davies; S J Hodges; R Williams; R Jalan
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

10.  Toll-like receptors in the pathogenesis of alcoholic liver disease.

Authors:  Jan Petrasek; Pranoti Mandrekar; Gyongyi Szabo
Journal:  Gastroenterol Res Pract       Date:  2010-08-17       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.